Sernova (Sernova) Debt-to-Asset : 0.03 (As of Jan. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Sernova Debt-to-Asset?

Sernova's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $0.07 Mil. Sernova's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $0.41 Mil. Sernova's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jan. 2024 was $13.84 Mil. Sernova's debt to asset for the quarter that ended in Jan. 2024 was 0.03.

Sernova Debt-to-Asset Historical Data

The historical data trend for Sernova's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Debt-to-Asset Chart

Sernova Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Debt-to-Asset

Get a 7-Day Free Trial

0.12

0.01

Sernova Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.03

Competitive Comparison of Sernova's Debt-to-Asset

For the Biotechnology subindustry, Sernova's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sernova's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sernova's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Sernova's Debt-to-Asset falls into.

Sernova Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Sernova's Debt-to-Asset for the fiscal year that ended in Oct. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.099	+	0)	/	16.122
	=	0.01

Sernova's Debt-to-Asset for the quarter that ended in Jan. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.066	+	0.407)	/	13.837
	=	0.03

Sernova (OTCPK:SEOVF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Sernova Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Sernova's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sernova (Sernova) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Corp (OTCPK:SEOVF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

PSH:Germany SVA:Canada

Address

700 Collip Circle, The Stiller Centre, Suite 114, London, ON, CAN, N6G 4X8

Website

https://www.sernova.com

Sernova Corp is a clinical-stage company developing products for the treatment of chronic debilitating diseases. The company is engaged in the research and development of its proprietary Cell Pouch and associated technologies including immune-protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and or hormones for the long-term treatment of multiple serious, chronic diseases such as diabetes, hemophilia, and thyroid disease.